B56 African trypanosomiasis

Name of the Condition

• African trypanosomiasis

Summary

African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease caused by protozoa of the genus Trypanosoma. The condition progresses through distinct stages, with early manifestations involving systemic symptoms and later stages affecting the central nervous system. It is endemic to sub-Saharan Africa and transmitted primarily by tsetse flies.

Causes

The disease is caused by infection with Trypanosoma brucei parasites, specifically T. b. gambiense (responsible for West African trypanosomiasis) and T. b. rhodesiense (responsible for East African trypanosomiasis). Transmission occurs through the bite of infected tsetse flies, which introduce the parasites into the bloodstream. The parasites multiply and spread, eventually crossing the blood-brain barrier in later stages.

Risk Factors

• Residence in or travel to endemic regions of sub-Saharan Africa.
• Prolonged outdoor exposure in rural areas where tsetse flies are prevalent.
• Lack of protective measures against insect bites, such as insect repellent or clothing.
• Occupational activities involving contact with tsetse fly habitats, such as farming or hunting.
• Immunocompromised states may increase susceptibility to severe disease.

Symptoms

• Initial stage: Fever, headache, joint pain, and itching at the bite site (chancre).
• Progressive: Swollen lymph nodes, fatigue, and intermittent fever.
• Neurological stage (if untreated): Confusion, personality changes, sleep disturbances, and motor impairment.

Diagnosis

Diagnosis involves a combination of clinical evaluation, microscopic examination of blood or lymph node aspirates for parasites, and serological tests to detect antibodies. Cerebrospinal fluid analysis is used to assess central nervous system involvement in later stages. Molecular methods, such as PCR, may be employed for confirmation in complex cases.

Treatment Options

Treatment depends on the disease stage and parasite subspecies. Early-stage disease is treated with pentamidine or suramin. Late-stage disease requires more toxic therapies, such as melarsoprol or eflornithine, often in combination. Supportive care, including management of neurological symptoms, is critical in advanced cases.

Prognosis and Follow-Up

With early diagnosis and appropriate treatment, the prognosis is generally favorable, though neurological damage may be irreversible in late-stage disease. Follow-up includes monitoring for treatment response and potential relapse, particularly in cases involving the central nervous system. Long-term neurological sequelae may persist even after successful treatment.

Complications

• Neurological damage, including cognitive impairment and motor dysfunction.
• Cardiac complications, such as myocarditis.
• Secondary infections due to immunosuppression.
• Severe anemia and organ failure in advanced cases.

Lifestyle & Prevention

• Avoid travel to endemic areas or use protective measures if unavoidable.
• Wear long-sleeved clothing and insect repellent to reduce tsetse fly bites.
• Sleep under insecticide-treated nets in high-risk regions.
• Seek prompt medical evaluation for symptoms after potential exposure.

When to Seek Professional Help

Seek immediate medical attention if you experience fever, headache, or other systemic symptoms after travel to sub-Saharan Africa, especially if accompanied by a bite from a tsetse fly. Early intervention is critical to prevent progression to the neurological stage.

Tips for Medical Coders

Document the specific subspecies (T. b. gambiense or T. b. rhodesiense) and disease stage (hemolymphatic or meningoencephalitic) when available, as these details may impact coding specificity. Ensure accurate capture of exposure history and diagnostic methods to support code assignment.